Investigation of Deteriorated Dissolution of Amorphous Itraconazole: Description of Incompatibility with Magnesium Stearate and Possible Solutions

Mol Pharm. 2017 Nov 6;14(11):3927-3934. doi: 10.1021/acs.molpharmaceut.7b00629. Epub 2017 Oct 16.

Abstract

Disadvantageous crystallization phenomenon of amorphous itraconazole (ITR) occurring in the course of dissolution process was investigated in this work. A perfectly amorphous form (solid dispersion) of the drug was generated by the electroblowing method (with vinylpyrrolidone-vinyl acetate copolymer), and the obtained fibers were formulated into tablets. Incomplete dissolution of the tablets was noticed under the circumstances of the standard dissolution test, after which a precipitated material could be filtered. The filtrate consisted of ITR and stearic acid since no magnesium content was detectable in it. In parallel with dissolution, ITR forms an insoluble associate, stabilized by hydrogen bonding, with stearic acid deriving from magnesium stearate. This is why dissolution curves do not have the plateaus at 100%. Two ways are viable to tackle this issue: change the lubricant (with sodium stearyl fumarate >95% dissolution can be accomplished) or alter the polymer in the solid dispersion to a type being able to form hydrogen bonds with ITR (e.g., hydroxypropyl methylcellulose). This work draws attention to one possible phenomenon that can lead to a deterioration of originally good dissolution of an amorphous solid dispersion.

Keywords: amorphous solid dispersion; crystallization; dissolution; magnesium stearate; oral delivery; tablet formulation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Crystallization
  • Drug Compounding
  • Excipients / chemistry
  • Itraconazole / chemistry*
  • Stearic Acids / chemistry*
  • Tablets / chemistry

Substances

  • Excipients
  • Stearic Acids
  • Tablets
  • Itraconazole
  • stearic acid